Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers

Regorafenib is a sorafenib-derived chemotherapy drug belonging to the multikinase inhibitor family. This agent effectively targets a wide range of tyrosine kinases involved in cancer biology, such as those implicated in oncogenesis, angiogenesis, and tumor microenvironment control. The beneficial ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Fondevila, Flavia, Méndez-Blanco, Carolina, Fernández-Palanca, Paula, González-Gallego, Javier, Mauriz, José L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802659/
https://www.ncbi.nlm.nih.gov/pubmed/31551425
http://dx.doi.org/10.1038/s12276-019-0308-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802659/
https://www.ncbi.nlm.nih.gov/pubmed/31551425
http://dx.doi.org/10.1038/s12276-019-0308-1

Ejemplares similares